#BRENIPATIDE
Big new trials from Lilly and Pittsburgh researchers will test whether GLP-1s can quell cravings for alcohol and drugs.
Big trials push beyond obesity to see if GLP-1s can quell alcohol, drug cravings
Eli Lilly tests brenipatide for alcohol use disorder & depression; CASPR/UPMC trials Novo's Wegovy for addiction. GLP-1 drugs show promise beyond metabolic disorders.
endpoints.news
October 22, 2026 at 7:26 PM
So fun fact. Brenipatide (originally referenced GLP1/GIP med)is being studied for multiple things in the mental health space. Schizophrenia, bipolar disorder, moderate/major depression, alcohol use disorder and opioid use disorder and finally smoking cessation.
October 18, 2026 at 7:12 PM
Can GLP-1s heal the brain? Obesity drugs get a makeover for addiction and depression
The quest for GLP-1 drugs that can treat brain disorders is getting a fresh infusion of energy and funding. Pharmaceutical companies have plunged into developing GLP-1-related compounds to treat addiction, schizophrenia, depression and other conditions — building on years of work by academic scientists. Last month, pharma giant Eli Lilly presented the first clinical results of brenipatide, a compound related to the company’s blockbuster obesity drug tirzepatide, for treatment of alcohol use disorder. Last week, biotechnology firm Kariya Pharmaceuticals shared early clinical results of a similar compound called KP405 for Parkinson’s disease. And biotechnology company Baseline Therapeutics plans to start a clinical trial in early 2027 of a GLP-1 compound for alcohol use disorder. Why do obesity drugs seem to treat so many other ailments? Researchers have long been interested in GLP-1 drugs’ potential against brain conditions. But, until recently, the pharmaceutical industry has not shared that interest, says Lorenzo Leggio, an addiction scientist at the National Institutes of Health in Baltimore, Maryland. The companies’ new focus on these therapies could accelerate access for people who could benefit from them, says Christian Hendershot, an addiction scientist at the University of Southern California in Los Angeles. “With the industry trials coming...
www.nature.com
October 14, 2026 at 12:39 AM
We're at a point now with GLP1 meds where weight loss seems like a given at this point, both VK2735 and Enicepatide posted very impressive weight loss numbers this week. But Brenipatide, is the real treat. It's been studying for substance use disorder, MENTAL HEALTH and respiratory diseases.
Brenipatide, VK2735 and Enicepatide
All hail the current and future GIP kings
the-incretins.beehiiv.com
September 24, 2026 at 1:41 PM
There are 13 Phase II & III studies in progress for brenipatide. Potential indications include alcohol use disorder, tobacco use disorder, opioid use disorder, major depressive disorder, bipolar disorder, schizophrenia, asthma, irritable bowel syndrome, & chronic obstructive pulmonary disease.
Lilly's GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders
Eli Lilly has presented early positive clinical data supporting once-weekly dosing for its GIP/GLP-1 receptor agonist candidate brenipatide in substance use, psychiatric, and immunologic disorders—and...
www.genengnews.com
September 21, 2026 at 12:06 PM
Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders

arc-codex.com
September 20, 2026 at 2:44 AM
GLPs have moved far beyond being viewed as simple w*ight-loss compounds.
R3TA changed the conversation by targeting three metabolic pathways. Now Eli Lilly is taking another step with Brenipatide (LY3537031)an experimental dual GIP/GLP-1 ag*nist being investigated for much more than body composition
September 10, 2026 at 12:57 AM
Oh look another Lilly trial for Brenipatide for an oddball indication, moderate to severe COPD!

(not that odd, respiratory diseases are worsened by obesity, same drug also being studied for asthma!)

GLP1 expressed in lung tissue + GIP antiinflammatory effect should show significant benefits.
ClinicalTrials.gov
clinicaltrials.gov
September 8, 2026 at 4:42 PM
Trial launches to evaluate Brenipatide, a weekly injectable candidate for asthma (Sponsored Content)
Trial launches to evaluate Brenipatide, a weekly injectable candidate for asthma - Think Local
A new Phase 2 clinical study is now enrolling adults with moderate to severe asthma to evaluate the safety and efficacy of Brenipatide, an investigational, once-weekly subcutaneous injection designed to target both asthma symptoms and weight-related factors that may contribute to disease severity.
www.castanet.net
March 20, 2026 at 7:03 AM
Yeah it's in development now. It's called Brenipatide and almost all the trials for it are for substance use disorder at this point.
June 8, 2026 at 9:02 PM
Eli Lilly yesterday talked up about every obesity/diabetes molecule in their portfolio except Brenipatide. Then I looked at the trials they're running last night and lo and behold 2 more trials! Now for IBS-D and IBS-C.

Seriously they are just flooding the zone for indications like I've never seen
May 1, 2026 at 2:04 PM
It's called Brenipatide and it now has 8 trials running mostly for SUD but also for adjunctive therapy for depression, bipolar and schizophrenia. Psych meds, especially for BPD and schizo are well known to increase lipids, cause weight gain and insulin resistance.
March 6, 2026 at 12:42 PM
Finally to wrap, couple notes, again the brenipatide for MDD, we get 4 topline readouts for retatrutide by late May 2026 and importantly the Kwikpen has been approved in the US. This is a multi-dose pen, this will save space for patients and making dosing easier than the autoinjectors
February 4, 2026 at 8:25 PM
How about a drug that can potentially treat, alcohol use disorder, smoking cessation, asthma, bipolar and major depression(not pictured, but talked about) Yeah that's brenipatide a GIP/GLP-1 dual agonist. Will it work? Who knows, but new depression/bipolar treatments are not common these days
February 4, 2026 at 8:25 PM
What's the next drug on the list after the GLP1s? Brenipatide is what Eli Lily is working on. After noticing that the weight loss drugs also helped some people (but not others) kick addictions, they moved to see x.com/PeptideList/... if they could find something adjacent to fight addiction.
x.com
April 13, 2026 at 10:10 AM
Trial launches to evaluate Brenipatide, a weekly injectable candidate for asthma (Sponsored Content)
Trial launches to evaluate Brenipatide, a weekly injectable candidate for asthma - Think Local
A new Phase 2 clinical study is now enrolling adults with moderate to severe asthma to evaluate the safety and efficacy of Brenipatide, an investigational, once-weekly subcutaneous injection designed to target both asthma symptoms and weight-related factors that may contribute to disease severity.
www.castanetkamloops.net
March 20, 2026 at 7:10 AM
Everyone's obsessed with Lilly's GLP-1s for weight loss. But brenipatide—their fourth molecule—might be the most important

Once-monthly dosing for addiction and psych. Lilly is so confident they jumped straight to P3

2028 will tell us if this actually works www.bigpharmasharma.com/p/the-glp-1-...
April 16, 2026 at 4:25 PM
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Clinical Trial #: NCT07286175
Sponsor(s): Eli Lilly and Company Status: Recruiting
go.psychconcierge.com
December 16, 2025 at 1:48 PM